Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction

More than 50% of patients with clinical heart failure have a preserved ejection fraction . Despite mortality that is similar to or slightly lower than heart failure with reduced ejection fraction , trials to date have not shown a therapy that imparts a mortality benefit in heart failure with preserved ejection fraction (HFpEF). HFpEF represents a heterogeneous disorder with a complex pathophysiologic basis, and this may contribute to the...